PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9534572

[Ribavirin administration by aerosol].

A Mora Pascual
View original source ↗Export metadata ↓

Abstract

This article presents the recommended procedures to administer ribavirin by means of an aerosol as followed at the Maternity-Childcare University Hospital in Vall d'Hebron, Barcelona. Ribavirin is a wide spectrum anitviral drug applied by aerosol means against severe infections caused by the respiratory syncytial virus. Said administering technique is complex and requires a considerable degree of nursing care, knowledge regarding its correct use, and hospital care. Bear in mind that careless administration of this drug can cause illness in the nurses who apply it. Therefore, it is necessary to follow the correct procedures described in this article.

Explore related subjects

Administration, InhalationAerosolsAntiviral AgentsChildDrug MonitoringHumansNebulizers and VaporizersRespiratory Syncytial Virus InfectionsRibavirinEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Mora Pascual. 1998. [Ribavirin administration by aerosol].. https://pubmed.ncbi.nlm.nih.gov/9534572/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗